Comparative Pharmacology
Head-to-head clinical analysis: FLOXIN IN DEXTROSE 5 versus MOXAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOXIN IN DEXTROSE 5 versus MOXAM.
FLOXIN IN DEXTROSE 5% vs MOXAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication and transcription.
Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, repair, and recombination.
400 mg intravenously every 12 hours.
400 mg orally every 24 hours for 7-14 days.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours (prolonged in renal impairment, up to 20-30 hours in severe impairment).
Terminal elimination half-life: 6-8 hours; prolonged in renal impairment (up to 20 hours with CrCl <30 mL/min).
Primarily renal (approximately 70-90% unchanged drug), with 5-10% biliary/fecal elimination.
Renal: ~70% unchanged; biliary/fecal: ~20% as unchanged drug and metabolites; minor metabolism via glucuronidation.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic